StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M) ($M)

Form 6-K / 20-F Therapy Area Product Sales Table

QuarterlyAnnual
Latest, Q2 2026
31
Period ended Jun 30, 2026
Change on a year earlier
-18.4%
38 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
18
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202631-18.4%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202640-51.8%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202559+31.1%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202540+8.1%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202538-7.3%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202583-7.8%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202445+45.2%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202437+15.6%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202441-10.9%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202490-13.5%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202331-90.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202332-76.1%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202346-80.1%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023104-83.5%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022321–Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022134–Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up vaccines & immune therapies / infectious disease (v&i / id) — emerging markets product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M) ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_vi_em

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.